Scientific Programme
Day 1 | Wednesday, 7 May 2025
| From 7:30 a.m. | Registration Counter open | |
| 09:00 - 09:15 a.m. | Opening remarks | Paul Hofman, France Klaus Pantel, Germany Catherine Alix-Panabières, France |
| 09:15 - 09:40 a.m. | Tracing tumor evolution by liquid biopsy | Klaus Pantel, Germany |
| Session 1 | Cancer Biology | |
| 09:40 - 10:05 a.m. | Therapeutic strategies for advanced carcinoma | Jean-Paul Thiery, France |
| 10:05 - 10:30 a.m. | TBA | Janine Erler, Denmark |
| 10:30 - 11:10 a.m. | Coffee Break | |
| Session 2 | Cancer Immunology | |
| 11:10 a.m. - 11:35 p.m. | Immuno-metabolites mediating anti-cancer immune responses | Sidonia Fagarasan, Japan |
| 11:35 a.m. - 12:00 p.m. | Liquid biopsy: pioneering the future of immuno-oncology with CTCs | Catherine Alix-Panabières, France |
| 12:00 p.m. - 12:15 p.m | Selected Abstract | |
| 12:15 p.m. - 12:30 p.m | Selected Abstract | |
| 12:30 - 02:00 p.m. | Lunch Break | |
| Session 3 | Minimal Residual Cancer Detection and Characterization | |
| 02:00 - 02:25 p.m. | Minimal residual disease in colon cancer: moving to the clinics | Clara Montagut, Spain |
| 02:25 - 02:50 p.m. | TRACERx insights into ultra-sensitive minimal residual disease detection | Charles Swanton, UK |
| 02:50 - 03:15 p.m. | Nation wide testing for ctDNA | Fabrice André, France |
| 03:15 - 03:30 p.m. | Selected Abstract | |
| 03:30 - 03:45 p.m. | Selected Abstract | |
| 03:45 - 04:10 p.m. | MRD in head and neck cancer: circulating tumor and HPV DNA | Lilian L. Siu, Canada |
| 04:10 - 04:35 p.m. | ctDNA in context of clinical response | Luis Diaz, USA |
| 04:35 - 05:00 p.m. | TBA | Benjamin Besse, France |
| 05:00 - 06:30 p.m. | Poster Session with Coffee | |
Day 2 | Thursday, 8 May 2025
| Session 4 | Early Detection of Cancer | |
| 09:00 - 09:25 a.m. | Sensitive detection of ctDNA | Nickolas Papadopoulos, USA |
| 09:25 - 09:50 a.m. | Epigenetic liquid biopsy | Yuval Dor, Israel |
| 09:50 - 10:15 a.m. | Developing multi-parametric cell-free DNA assays for early detection of breast, ovarian and lung cancer in populations at high risk | Nitzan Rosenfeld, UK |
| 10:15 - 10:30 a.m. | Selected Abstract | |
| 10:30 - 10:45 a.m. | Selected Abstract | |
| 10:45 - 11:15 a.m. | Coffee Break | |
| Session 5 | Liquid Biopsy and Immunotherapy | |
| 11:15 - 11:40 a.m. | Liquid biopsy in cancer immunotherapy | Raphael López López, Spain |
| 11:40 a.m. - 12:05 p.m. | Monitoring immunotherapies with liquid biopsies: the experience of Sapienza University of Rome | Paola Gazzaniga, Italy |
| 12:05 - 12:30 p.m. | Ultra-sensitive ctDNA profiling in melanoma undergoing immune-checkpoint inhibition | Christoffer Gebhardt, Germany |
| 12:30 - 12:45 p.m. | Selected Abstract | |
| 12:45 - 01:00 p.m. | Selected Abstract | |
| 01:00 - 02:30 p.m. | Lunch Break | |
| Session 6 | Risk Assessment and Monitoring of Cancer Therapies | |
| 02:30 - 02:55 p.m. | TBA | Sonja Loges, Germany |
| 02:55 - 03:20 p.m. | Multimodal liquid biopsy analysis in children with cancer using long-read sequencing on a national scale | Carolin Sauer, UK |
| 03:20- 03:45 p.m. | Real-world usefulness of CGP liquid biopsies on site in thoracic oncology | Paul Hofman, France |
| 03:45- 04:00 p.m. | Selected Abstract | |
| 04:00- 04:15 p.m. | Selected Abstract | |
| 04:15 - 04:40 p.m. | Multidimensional evaluation of circulating tumor DNA | Umberto Malapelle, Italy |
| 04:40 - 05:05 p.m. | Clinical utility of liquid biopsy in breast cancer | Jean-Yves Pierga, France |
| 05:05 - 06:35 p.m. | Poster Session with Coffee | |
Day 3 | Friday, 9 May 2025
| Session 7 | Perspectives of Liquid Biopsy - Part I | |
| 09:30 - 09:55 a.m. | Inferring complex tumor states in lung cancer using cfDNA methylation from liquid biopsies | Simon Heeke, USA |
| 09:55 - 10:20 a.m. | Transforming cancer patient management: the intersection of AI and liquid biopsy | Nuria Malats, Spain |
| 10:20 - 10:45 a.m. | Extracellular vesicles | An Hendrix, Belgium |
| 10:45 - 11:15 a.m. | Coffee Break | |
| Perspectives of Liquid Biopsy - Part II | ||
| 11:15 - 11:40 a.m. | Establishing a recurrence prevention measure for colorectal cancer after radical surgery by targeting the tumor microenvironment | Koshi Mimori, Japan |
| 11:40 a.m. - 12:05 p.m. | TBA | Howard Scher, USA |
| 12:05 - 12:30 p.m. | TBA | Nicola Normanno, Italy |
| 12:30 - 12:55 p.m. | Scientific and clinical aspects of using ctDNA MRD in oncology | Karen-Lise Garm-Spindler, Denmark |
| 12:55 - 01:05 p.m. | Young Investigator Awards | |
| 01:05 - 01:15 p.m. | Concluding Remarks | Paul Hofman, France Klaus Pantel, Germany Catherine Alix-Panabières, France |